Professional
Added to YB: 2024-02-20
Pitch date: 2024-02-15
RPRX [bullish]
Royalty Pharma plc
+34.16%
current return
Author Info
No bio for this author
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Market Cap
$14.0B
Pitch Price
$28.61
Price Target
52.00 (+35%)
Dividend
2.64%
EV/EBITDA
N/A
P/E
13.58
EV/Sales
10.44
Sector
Pharmaceuticals
Category
growth
Royalty Pharma plc: Diverse Portfolio Supports Long-Term Growth
RPRX Q4 beat est, maintains $52 FV. Diverse portfolio grew 9% to $3B in '23 despite Vertex royalty dispute. 7 deals worth $4B in '23, $2.6B/yr deployment thru '28. Narrow moat from approved biopharma royalties w/ long exclusivity. Disciplined capital allocation, stable BS. Risks: regulation, defaults.
Read full article (9 min)